Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro
N Zhang, K Erjala, J Kulmala, X Qiu, M Sundvall… - Radiotherapy and …, 2009 - Elsevier
BACKGROUND AND PURPOSE: For locoregionally advanced HNSCC, chemoradiotherapy
with cisplatin or another platinum compound is considered as one of the standard treatment …
with cisplatin or another platinum compound is considered as one of the standard treatment …
Cetuximab in the treatment of head and neck cancer
J Bernier - Expert review of anticancer therapy, 2006 - Taylor & Francis
Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …
The role of cetuximab in the treatment of squamous cell cancer of the head and neck
B Burtness - Expert opinion on biological therapy, 2005 - Taylor & Francis
The epidermal growth factor receptor (EGFR) is a member of the HER family of tyrosine
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …
kinase growth factor receptors. Binding to EGFR by its natural ligands, mainly epidermal …
Cetuximab in the treatment of squamous cell carcinoma of the head and neck
P Specenier, JB Vermorken - Expert review of anticancer therapy, 2011 - Taylor & Francis
The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …
[HTML][HTML] Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study
Background Intensification of chemoradiation for advanced head and neck squamous cell
carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy …
carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy …
[HTML][HTML] The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck
R Mehra, RB Cohen, BA Burtness - Clinical advances in …, 2008 - ncbi.nlm.nih.gov
Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …
[PDF][PDF] Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck
C Matuschek, E Bölke, C Belka… - Strahlentherapie und …, 2013 - academia.edu
The management of squamous cell cancer of the head and neck (SCCHN) has become
increasingly complex, because combined interdisciplinary treatment approaches including …
increasingly complex, because combined interdisciplinary treatment approaches including …
Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with …
JA Bonner, PM Harari, J Giralt, N Azarnia… - Journal of Clinical …, 2004 - ascopubs.org
5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck
JE Frampton - Drugs, 2010 - Springer
Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
F Rivera, A García-Castaño, N Vega… - Expert review of …, 2009 - Taylor & Francis
Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …